GUBRAC Stock Overview
Operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Gubra A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 688.00 |
| 52 Week High | DKK 728.00 |
| 52 Week Low | DKK 256.00 |
| Beta | 0 |
| 1 Month Change | 12.42% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 338.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| GUBRAC | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | -4.4% | -1.5% |
| 1Y | n/a | -27.0% | 3.5% |
Return vs Industry: Insufficient data to determine how GUBRAC performed against the UK Life Sciences industry.
Return vs Market: Insufficient data to determine how GUBRAC performed against the UK Market.
Price Volatility
| GUBRAC volatility | |
|---|---|
| GUBRAC Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: GUBRAC's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine GUBRAC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 235 | Henrik Blou | www.gubra.dk |
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs in Denmark and internationally. The company operates through CRO, Discovery & Partnerships, and Gubra Green segments. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, assays and molecular pharmacology, bioinformatics, bioanalysis, next gen sequencing, and 2D and 3D imaging.
Gubra A/S Fundamentals Summary
| GUBRAC fundamental statistics | |
|---|---|
| Market cap | DKK 11.87b |
| Earnings (TTM) | -DKK 46.53m |
| Revenue (TTM) | DKK 223.82m |
53.0x
P/S Ratio-255.2x
P/E RatioIs GUBRAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUBRAC income statement (TTM) | |
|---|---|
| Revenue | DKK 223.82m |
| Cost of Revenue | DKK 92.35m |
| Gross Profit | DKK 131.47m |
| Other Expenses | DKK 177.99m |
| Earnings | -DKK 46.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 28, 2025
| Earnings per share (EPS) | -2.85 |
| Gross Margin | 58.74% |
| Net Profit Margin | -20.79% |
| Debt/Equity Ratio | 0% |
How did GUBRAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 18:50 |
| End of Day Share Price | 2024/12/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gubra A/S is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|